Alerts

Justice to Target Corporations and C-Suite Executives in the Healthcare Industry

Alerts / May 19, 2015

On Thursday, May 14, 2015, at a meeting of the American Bar Association’s Healthcare Fraud Section, Leslie Caldwell, the Assistant Attorney General for the Department of Justice (DOJ) Criminal Division, declared stamping out healthcare “fraud and holding those who commit this fraud accountable are core missions of the Criminal Division and the Justice Department.” In addition to the ongoing operations of her team of more than 40 specialized healthcare prosecutors at the DOJ, Medicare Fraud Strike Force, and local United States Attorneys’ Offices, AAG Caldwell also described a renewed and intensified focus on executives and corporations:

The Strike Force will follow evidence of healthcare fraud wherever it leads, including into corporate boardrooms and executive suites. The Criminal Division has a long record of holding executives responsible for their criminal wrongdoing in cases involving financial fraud. You should expect to see us building on that record in the field of healthcare fraud.

No stranger to corporate prosecutions, as the former director of the Enron Task Force, AAG Caldwell cited the immense resources at her disposal for combating healthcare fraud across the country. Pointing to more than a dozen active corporate healthcare fraud investigations currently under way at DOJ, she made clear that the bar should expect to see more action in this area. AAG Caldwell has reason to be optimistic about the overall success of her renewed healthcare focus, as the Strike Force has made an imposing start:

In the last fiscal year alone, the Strike Force charged 353 defendants. Of those 353 defendants charged, 304 pleaded guilty and 41 were convicted at trial. The Strike Force has an overall conviction rate of 95 percent—a spectacular rate of success considering the volume and the complexity of the prosecutions—and secures prison sentences averaging more than 50 months.

AAG Caldwell further stressed the importance of cooperation for companies that have discovered healthcare fraud, noting “put simply, companies seeking credit for cooperation must conduct a thorough internal investigation and turn over all available evidence of wrongdoing to our prosecutors in a timely and complete way.” The hallmarks of cooperation, she emphasized, were candor and completeness. According to AAG Caldwell, DOJ will expand its geographic scrutiny of potential fraud hot spots to include New York, Dallas, Houston, Detroit, Chicago, and Los Angeles, meaning more companies are going to be under increased scrutiny than ever before.

With AAG Caldwell’s remarks in mind, it is incumbent on all healthcare companies and executives to implement and enforce rigorous compliance policies and programs. In many ways the vanguard of fraud prosecutions, AAG Caldwell also stressed the importance of cybersecurity measures to prevent the fraudulent acquisition or use of patient data. This latter aspect is likely to permeate all fraud prosecutions in the future, as companies face increased pressure to protect client and customer data, but it is nowhere more scrutinized at this time than in the healthcare sector.

BakerHostetler represents and counsels healthcare clients on a variety of state and federal fraud and abuse matters, including False Claims Act litigation, the federal Anti-Kickback Statute, the federal physician self-referral law known as the Stark Law, and the Civil Monetary Penalties Law. The Healthcare Industry team has deep experience in the healthcare sector and defending providers against allegations of fraud. The firm’s White Collar Defense and Corporate Investigations team is co-chaired by the former Chief of the Securities and Healthcare Fraud Unit for the Office of the United States Attorney for the District of New Jersey.

If you have any questions about this alert, please contact John J. Carney at jcarney@bakerlaw.com or 212.589.4255; George A. Stamboulidis at gstamboulidis@bakerlaw.com or 212.589.4211; Christopher J. Swift at cswift@bakerlaw.com at 216.861.7461; B. Scott McBride at smcbride@bakerlaw.com at 713.646.1390; Noah D. Rosenberg at nrosenberg@bakerlaw.com or 310.442.8867; or any member of BakerHostetler's White Collar Defense and Corporate Investigations or Healthcare Industry teams.

Authorship Credit: John J. Carney and Kaitlyn A. Ferguson

 


Baker & Hostetler LLP publications are intended to inform our clients and other friends of the firm about current legal developments of general interest. They should not be construed as legal advice, and readers should not act upon the information contained in these publications without professional counsel. The hiring of a lawyer is an important decision that should not be based solely upon advertisements. Before you decide, ask us to send you written information about our qualifications and experience.

 

Blog

In The Blogs

Previous Next
Health Law Update
Capitol Hill Healthcare Update
December 2, 2019
HEALTH PROVISIONS FACE UNCERTAINTY AS CONGRESS RETURNS FOR BUSY DECEMBER Lawmakers return to Washington this week after the Thanksgiving holiday with only 18 days before the government runs out of money – and that’s not even the most...
Read More ->
Health Law Update
Capitol Hill Healthcare Update
November 18, 2019
FDA NOMINATION HEARING DRIVES THE WEEK IN HEALTH POLICY President Trump’s nominee to lead the Food and Drug Administration, Dr. Stephen Hahn, will appear Wednesday before the Senate Health, Education, Labor and Pensions Committee for a...
Read More ->
Health Law Update
Capitol Hill Healthcare Update
November 12, 2019
COMPREHENSIVE DRUG BILL STALLS WHILE HOUSE PUSHES SMALLER MEASURES House Democrats are planning to take up more narrow bills addressing prescription drug costs while their broad legislation is delayed as the Congressional Budget Office...
Read More ->
Health Law Update
Capitol Hill Healthcare Update
October 28, 2019
DEMOCRATS PRESS FOR PRE-THANKSGIVING VOTE ON DRUG PRICING BILL The House Ways and Means Committee last week approved an amended version of legislation that would overhaul how Medicare and private insurers reimburse for prescription drugs...
Read More ->
Health Law Update
Capitol Hill Healthcare Update
September 23, 2019
PELOSI INTRODUCES DRUG PRICING BILL WHILE TRUMP PUSHES SENATE VERSION House Democrats introduced legislation last week to lower prescription drug prices – including allowing Medicare to negotiate prices with manufacturers – and set an...
Read More ->